Equities research analysts forecast that Acorda Therapeutics Inc (NASDAQ:ACOR) will report earnings per share of ($0.75) for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Acorda Therapeutics’ earnings, with the highest EPS estimate coming in at $0.13 and the lowest estimate coming in at ($1.20). Acorda Therapeutics reported earnings per share of $0.61 during the same quarter last year, which suggests a negative year-over-year growth rate of 223%. The company is expected to announce its next quarterly earnings report on Thursday, February 21st.
On average, analysts expect that Acorda Therapeutics will report full-year earnings of $0.94 per share for the current financial year, with EPS estimates ranging from $0.50 to $1.84. For the next year, analysts anticipate that the company will post earnings of ($3.83) per share, with EPS estimates ranging from ($5.00) to ($2.75). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last issued its earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.15. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. The business had revenue of $142.80 million for the quarter, compared to the consensus estimate of $82.74 million. During the same period in the prior year, the firm earned $0.43 EPS. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year.
Several equities research analysts have recently weighed in on ACOR shares. HC Wainwright set a $31.00 price target on shares of Acorda Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 6th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $32.00 price target on shares of Acorda Therapeutics in a research report on Monday, September 10th. TheStreet cut shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, October 5th. ValuEngine cut shares of Acorda Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Finally, Oppenheimer set a $18.00 price target on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Sunday, September 23rd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $23.92.
In related news, major shareholder Scopia Capital Management Lp sold 143,576 shares of the stock in a transaction that occurred on Thursday, October 11th. The shares were sold at an average price of $16.98, for a total transaction of $2,437,920.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 490,832 shares of company stock valued at $9,121,364 in the last three months. 7.80% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. NumerixS Investment Technologies Inc increased its stake in Acorda Therapeutics by 123.5% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,800 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,100 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in Acorda Therapeutics during the 2nd quarter valued at approximately $132,000. Dynamic Technology Lab Private Ltd acquired a new position in Acorda Therapeutics during the 2nd quarter valued at approximately $218,000. Crossmark Global Holdings Inc. acquired a new position in Acorda Therapeutics during the 2nd quarter valued at approximately $229,000. Finally, Sun Life Financial INC acquired a new position in Acorda Therapeutics during the 2nd quarter valued at approximately $237,000.
Shares of ACOR traded up $0.21 during mid-day trading on Wednesday, hitting $20.79. The company’s stock had a trading volume of 36,668 shares, compared to its average volume of 901,097. Acorda Therapeutics has a 52-week low of $15.60 and a 52-week high of $36.35. The stock has a market capitalization of $924.03 million, a PE ratio of 19.99 and a beta of 1.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.95 and a current ratio of 4.03.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
Read More: Short Selling – Explanation For Shorting Stocks
Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.